RE:RE:RE:RE:RE:RE:RE:FROM Q2 2018 Results - Earnings Callsunshine7 wrote: The ironic thing is that partnerships come with a cost... to future earnings. Not sure which is worse when confident with the pipeline. The fact is that bios spend Billions and years to develope a drug with a 10% probability of success. PLI seems to be in a very good position in this regard.
Put a value on this and divide by 1B shares with a 50% probability and you get a number much higher than todays SP.
PL needs to get his head out of his butt and stop playing like he needs to go for the hail mary pass. He clearly doesn't plan for possible problems like the FDA fast track delay.
PL also needs to stop taking the shareholders for granted and pretending it's ok to go on like a drop of 200-300% is acceptable.
PL should focus on stability and developing a discernable path to getting these drugs to market.
Push for a partnership, get their fast track back on target then in the future consider dilution/NASDAQ once he's proven he can get things done properly.